Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18007534 | 0.83 | CA2 (0.51) | CA2ALDH1A1HTT | |
| SCHEMBL7671211 | 0.82 | CA2 (0.40) | CA2STSCHRM2CHRM4CHRM5 | |
| SCHEMBL22265866 | 0.80 | CA2 (0.60) | CA2STSCA1CA12CA9 | |
| SCHEMBL21586454 | 0.71 | CA2 (0.58) | CA2CA1CA12CA9ALDH1A1 | |
| SCHEMBL4486306 | 0.69 | — | — | |
| SCHEMBL13185509 | 0.68 | ALDH1A1 (0.40) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9372431 | 0.67 | — | — | |
| SCHEMBL7137002 | 0.67 | CA2 (0.50) | CA2STSCA1CA12CA9 | |
| SCHEMBL27430354 | 0.67 | NLRP3 (0.44) | CA2 | |
| SCHEMBL24743674 | 0.67 | CA2 (0.45) | CA2CA1CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760735-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-09-19 | — | — | US | disclosed |
| CN-1113877-C | Effective synthetic method for furau sulfonic acid amide compound for synthesizing new IL-1 inhibitor | PFIZER PRODUCTS CO (US) | 2003-07-09 | — | — | CN | disclosed |
| EP-1214087-A1 | COMBINATION TREATMENT WITH IL-1RA AND COMPOUNDS THAT INHIBIT IL-1 PROCESSING AND RELEASE | Pfizer Products Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| CN-1244526-A | Effective synthetic method for furau sulfonic acid amide compound for synthesizing new IL-1 inhibitor | PFIZER PRODUCTS CO (US) | 2000-02-16 | — | — | CN | disclosed |
| US-6022984-A | Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors | PFIZER INC. (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0976742-A1 | A synthesis of furan sulfonamide compounds useful in the synthesis of IL-1 inhibitors | Pfizer Products Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760735-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CA2 1332/4885STS 3301/4885CA1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.